DLB
Dolby Laboratories, Inc.
DLB's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over DLB overall, supported by stronger modeled upside and stronger fundamentals.
DLB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
DLB's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
DLB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $64.59 | — |
| Cheap | 27x | $62.50 | -3.2% |
| Current | 28x | $64.59 | — |
| Fair | 32x | $74.76 | +16% |
| Expensive | 40x | $94.26 | +46% |
Historical ranges are pointers, not guarantees.
DLB's PE is in its cheap range at 28x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over DLB in the historical PE scenario, which offers more potential upside but is not a forecast.
DLB Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect DLB's earnings to grow and its profitability to improve, with its revenue holding steady.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
DLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.58 | +96% |
| Q2 2026 | $2.34 | -14% |
| Q1 2026 | $2.52 | -4.2% |
| Q4 2025 | $2.47 | -8.5% |
| Q3 2025 | $2.62 | -2.6% |
| Q2 2025 | $2.71 | +24% |
| Q1 2025 | $2.63 | +35% |
| Q4 2024 | $2.70 | +41% |
| Q3 2024 | $2.69 | +31% |
DLB earned $2.34 per share over the past year, down 14% from the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over DLB on earnings, with more consistent year-over-year improvement.
DLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $305M | -3.3% |
| Q1 2026 | $395.6M | +7.1% |
| Q4 2025 | $346.7M | -2.9% |
| Q3 2025 | $307M | +0.7% |
| Q2 2025 | $315.5M | +9.3% |
| Q1 2025 | $369.6M | +1.4% |
| Q4 2024 | $357M | +13% |
| Q3 2024 | $304.8M | +4.9% |
DLB's revenue grew through 2023 and has held roughly level since: $305M last quarter, down 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 11% | -3.8 points |
| Q1 2026 | 29% | -0.6 points |
| Q4 2025 | 18% | -4.4 points |
| Q3 2025 | 9.7% | -5.5 points |
| Q2 2025 | 15% | +2.4 points |
| Q1 2025 | 29% | -0.7 points |
| Q4 2024 | 22% | +1.4 points |
| Q3 2024 | 15% | +16 points |
DLB's operating margin was 11% last quarter, down 3.8 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over DLB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over DLB on profitability, with a higher operating margin.
DLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $152.5M | +149% |
| Q1 2026 | $83.4M | -50% |
| Q4 2025 | $50.2M | -50% |
| Q3 2025 | $106.6M | -2% |
| Q2 2025 | $61.3M | +349% |
| Q1 2025 | $168M | -2.6% |
| Q4 2024 | $100M | +4229% |
| Q3 2024 | $108.8M | +42% |
DLB's free cash flow has been positive every quarter for seven years: $393M over the past year, down 10% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over DLB on cash flow, with more consistent year-over-year improvement.
DLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -997K shares |
| 1 year | -2.5% | -2.4M shares |
| 3 years | -3% | -2.9M shares |
| 5 years | -9.7% | -10.1M shares |
| Available history | -8.2% | -8.4M shares |
DLB has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $65M |
| Q1 2026 | $65M |
| Q4 2025 | $70M |
| Q3 2025 | $35M |
| Q2 2025 | $40M |
| Q1 2025 | $35M |
| Q4 2024 | $15M |
| Q3 2024 | $20M |
DLB spent $235M buying back its own shares over the past year, up 114% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
DLB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -1.7x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -2.0x | Net Cash |
| Q2 2025 | -1.9x | Net Cash |
| Q1 2025 | -1.8x | Net Cash |
| Q4 2024 | -1.5x | Net Cash |
| Q3 2024 | -1.4x | Net Cash |
DLB has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
DLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.5 | Neutral |
| Stochastic | 78.1 | Neutral |
DLB's weekly RSI is 58 (neutral) and its Stochastic is 78 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
DLB PE vs Technology Sector
| Metric | DLB | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 28x | 0.9% below |
| PE % | 22 | 35 | 13 pts below |
DLB is trading at 28x earnings, in line with the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over DLB on valuation relative to its sector.
DLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.3 | 5.4% above |
| 20 week MA | $59.2 | 9.1% above |
| 50 week MA | $60.3 | 7.1% above |
| 100 week MA | $67.5 | 4.4% below |
| 200 week MA | $74.3 | 13% below |
DLB has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
DLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.3 | $95.3 | +39% |
| 2021 | $95.3 | $92.7 | -2.7% |
| 2022 | $92.7 | $69.2 | -25% |
| 2023 | $69.2 | $86.2 | +24% |
| 2024 | $86.2 | $78.5 | -8.9% |
| 2025 | $78.5 | $65.7 | -16% |
| 2026 YTD | $65.7 | $64.6 | -1.7% |
DLB has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.